Logo

Gilead and Jounce's JTX-1811 Receives US FDA's IND Clearance for Cancer Immunotherapies

Share this
Gilead and Jounce's JTX-1811 Receives US FDA's IND Clearance for Cancer Immunotherapies

Gilead and Jounce's JTX-1811 Receives US FDA's IND Clearance for Cancer Immunotherapies

Shots:

  • Jounce to receive $85M upfront and $35M in its common stock under the terms of Sep 2020 agreement. Additionally- it is eligible to receive upto $660M in future clinical- regulatory and commercial milestone payments along with royalties based upon the w/w sales after receiving a $25M milestone
  • Jounce led the development of JTX-1811 through IND clearance- and thereafter Gilead has exclusive rights to develop and commercialize the program
  • JTX-1811 is a mAb- targeting CCR8 and selectively deplete immunosuppressive tumor-infiltrating T regulatory (TITR) cells

  | Ref: Globe Newswire | Image: Gilead

Click here to­ read the full press release 

Tuba

Tuba was Senior Editor at PharmaShots. She was curious, creative, and passionate about recent updates and innovations in the life sciences industry. She covered Biopharma, MedTech, and Digital health segments. Tuba also had an experience in digital and social media marketing and ran the campaigns independently. She can be contacted at connect@pharmashots.com.

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions